AI predicts abiraterone benefit for prostate cancer patients

An AI tool can now predict which men with prostate cancer will benefit from the drug abiraterone, potentially halving their risk of death. This breakthrough could expand access to the life-extending treatment. The AI analyzes tumor images to identify men most likely to respond to abiraterone, a drug that has shown significant benefits. The test was trialed on over 1,000 men, and the drug cut the risk of death for those with biomarker-positive tumors. The research, presented at a major cancer conference, could lead to wider availability of abiraterone, especially in England where it is not yet widely available for certain prostate cancer cases. The drug is relatively inexpensive.